↓ Skip to main content

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult…

Overview of attention for article published in Cochrane database of systematic reviews, September 2012
Altmetric Badge

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
101 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
Published in
Cochrane database of systematic reviews, September 2012
DOI 10.1002/14651858.cd008516.pub2
Pubmed ID
Authors

Lior H Katz, Hadar Goldvaser, Anat Gafter‐Gvili, Ran Tur‐Kaspa

Abstract

The standard length of peginterferon plus ribavirin treatment for chronic hepatitis C virus (HCV) genotype 1 infected patients is 48 weeks. However, the number of patients demonstrating a sustained virological response is not high. In order to improve sustained virological response, extending the length of the treatment period has been suggested.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 101 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 12%
Student > Bachelor 11 11%
Student > Postgraduate 8 8%
Student > Ph. D. Student 8 8%
Researcher 6 6%
Other 20 20%
Unknown 36 36%
Readers by discipline Count As %
Medicine and Dentistry 31 31%
Nursing and Health Professions 10 10%
Psychology 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Agricultural and Biological Sciences 3 3%
Other 10 10%
Unknown 38 38%